Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products
DEA proposes to remove exemption status for inactive butalbital products, reclassifying them as controlled substances. This directly impacts dietary supplement brands, contract manufacturers, private-label sellers, and ingredient suppliers that handle or formulate with butalbital, even in inactive forms. Immediate review of product compositions and supply chains is required.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 5, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers that use or distribute butalbital in any form (including inactive). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends 60 days from publication (July 25, 2026). Final rule effective 30 days after publication. Immediate action recommended.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA proposes to revoke the exempted status for certain nonnarcotic prescription products containing butalbital, meaning these products would be reclassified as controlled substances under the Controlled Substances Act.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers that use or distribute butalbital in any form (including inactive).
What you must do
Identify any products containing butalbital (including inactive ingredients), assess supply chain exposure, and prepare for compliance with controlled substance regulations (e.g., registration, security, recordkeeping).
Deadline
Comment period ends 60 days from publication (July 25, 2026). Final rule effective 30 days after publication. Immediate action recommended.
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trial